Table 1 Inhibitory concentration (IC50) of the Antp-TPR
From: Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent
Antitumor activity, IC50 (μM) * | ||
|---|---|---|
Cell lines | TPR | Antp-TPR |
Normal cells | Â | Â |
HEK293T | - | >100 |
MRC5 | - | >100 |
PE | - | >100 |
Breast cancer | Â | Â |
T47D | - | 19.4 |
BT20 | - | 37.4 |
MDA-MB-231 | - | 56.9 |
Pancreatic cancer | Â | Â |
BXPC3 | - | 44.8 |
Renal cancer | Â | Â |
Caki-1 | - | 47.9 |
Lung cancer | Â | Â |
A549 | - | 65.9 |
Prostate cancer | Â | Â |
LNcap | - | 56.7 |
Gastric cancer | Â | Â |
OE19 | - | 33.4 |